Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets

Diabetic nephropathy (DN) is one of the major microvascular complications of diabetes mellitus and the leading cause of end-stage kidney disease. The standard treatments for diabetic patients are glucose and blood pressure control, lipid lowering, and renin-angiotensin system blockade; however, thes...

Full description

Bibliographic Details
Main Authors: Carlamaria Zoja, Christodoulos Xinaris, Daniela Macconi
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.586892/full
id doaj-04253511564444b3b968b905ca10bb30
record_format Article
spelling doaj-04253511564444b3b968b905ca10bb302021-01-15T15:23:49ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-12-011110.3389/fphar.2020.586892586892Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic TargetsCarlamaria Zoja0Christodoulos Xinaris1Christodoulos Xinaris2Daniela Macconi3Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, ItalyIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, ItalyUniversity of Nicosia Medical School, Nicosia, CyprusIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, ItalyDiabetic nephropathy (DN) is one of the major microvascular complications of diabetes mellitus and the leading cause of end-stage kidney disease. The standard treatments for diabetic patients are glucose and blood pressure control, lipid lowering, and renin-angiotensin system blockade; however, these therapeutic approaches can provide only partial renoprotection if started late in the course of the disease. One major limitation in developing efficient therapies for DN is the complex pathobiology of the diabetic kidney, which undergoes a set of profound structural, metabolic and functional changes. Despite these difficulties, experimental models of diabetes have revealed promising therapeutic targets by identifying pathways that modulate key functions of podocytes and glomerular endothelial cells. In this review we will describe recent advances in the field, analyze key molecular pathways that contribute to the pathogenesis of the disease, and discuss how they could be modulated to prevent or reverse DN.https://www.frontiersin.org/articles/10.3389/fphar.2020.586892/fulldiabetic nephropathyrenin-angiotensin systemangiotensin 1–7sirtuinsnotch signalingthyroid hormone signaling
collection DOAJ
language English
format Article
sources DOAJ
author Carlamaria Zoja
Christodoulos Xinaris
Christodoulos Xinaris
Daniela Macconi
spellingShingle Carlamaria Zoja
Christodoulos Xinaris
Christodoulos Xinaris
Daniela Macconi
Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets
Frontiers in Pharmacology
diabetic nephropathy
renin-angiotensin system
angiotensin 1–7
sirtuins
notch signaling
thyroid hormone signaling
author_facet Carlamaria Zoja
Christodoulos Xinaris
Christodoulos Xinaris
Daniela Macconi
author_sort Carlamaria Zoja
title Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets
title_short Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets
title_full Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets
title_fullStr Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets
title_full_unstemmed Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets
title_sort diabetic nephropathy: novel molecular mechanisms and therapeutic targets
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2020-12-01
description Diabetic nephropathy (DN) is one of the major microvascular complications of diabetes mellitus and the leading cause of end-stage kidney disease. The standard treatments for diabetic patients are glucose and blood pressure control, lipid lowering, and renin-angiotensin system blockade; however, these therapeutic approaches can provide only partial renoprotection if started late in the course of the disease. One major limitation in developing efficient therapies for DN is the complex pathobiology of the diabetic kidney, which undergoes a set of profound structural, metabolic and functional changes. Despite these difficulties, experimental models of diabetes have revealed promising therapeutic targets by identifying pathways that modulate key functions of podocytes and glomerular endothelial cells. In this review we will describe recent advances in the field, analyze key molecular pathways that contribute to the pathogenesis of the disease, and discuss how they could be modulated to prevent or reverse DN.
topic diabetic nephropathy
renin-angiotensin system
angiotensin 1–7
sirtuins
notch signaling
thyroid hormone signaling
url https://www.frontiersin.org/articles/10.3389/fphar.2020.586892/full
work_keys_str_mv AT carlamariazoja diabeticnephropathynovelmolecularmechanismsandtherapeutictargets
AT christodoulosxinaris diabeticnephropathynovelmolecularmechanismsandtherapeutictargets
AT christodoulosxinaris diabeticnephropathynovelmolecularmechanismsandtherapeutictargets
AT danielamacconi diabeticnephropathynovelmolecularmechanismsandtherapeutictargets
_version_ 1724336671251496960